ArticleJournal of lipid research2026
E3 ligase SMURF2 promotes adipogenesis and improves obesity complications by suppressing TGF-β signaling.
Article in Journal of lipid research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enhanced TGF-β/SMAD signaling causes adipose dysfunction by inhibiting adipogenesis and promoting adipocyte pathological hypertrophy in obesity development. Identifying novel regulators of the TGF-β pathway could significant important for modulating adipose metabolism. While ubiquitination of SMAD attenuates TGF-β signaling, it is still unknown whether this mechanism is involved in regulating adipose function. This study revealed that SMAD proteins undergo ubiquitination and degradation during the early stages of adipogenesis. E3 ligase SMURF2 was identified as the primary regulator in this biological process. In vitro studies demonstrated that SMURF2 deficiency significantly impaired adipogenic differentiation of preadipocytes, whereas SMURF2 overexpression markedly enhanced this process. In mouse studies, SMURF2 overexpression robustly promoted de novo adipogenesis, which in turn conferred resistance to high-fat diet-induced obesity and metabolic disorders. Furthermore, increased SMURF2 expression significantly improved and therapeutically ameliorated dysregulated glucose and lipid metabolism in obese mice. Interestingly, we designed a peptide to inhibit SMAD2 phosphorylation, thereby preventing its ubiquitination by SMURF2. Administration of this polypeptide conferred substantial metabolic benefits in obese mice. Our study uncovers a novel regulatory axis controlling adipose tissue expansion via the TGF-β/SMAD pathway. We anticipate that the findings from this project will provide new targets and insights for intervening in obesity and its metabolic complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.